Enflonsia is an extended half-life RSV fusion glycoprotein neutralizing monoclonal antibody that is designed to provide durable protection through 5 months.

A letter to the US public on the AMA website, signed by 75+ medical societies, stresses the vital importance of influenza, RSV, and COVID-19 vaccines.

An outside group of experts agreed that the CDC should recommend a new antibody drug that offers protection against RSV for ...

Protection against RSV derived from preF IgG antibodies waned 6 months after infection in an analysis of patients with confirmed disease and household contacts.

RSV seasons ended earlier than usual in 2022-23 and 2023-24, and typical human hMPV circulation patterns have returned since the COVID-19 pandemic.

U.S. Health Secretary Robert F. Kennedy Jr.'s newly revamped vaccine advisory panel voted on Thursday to recommend Americans ...

Enjoy, and see you soon… A fast-growing group of Americans is turning to what many call the “gray market” for obesity ...

The Center for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), and its eight new ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

Studies have found important benefits from the new RSV immunization and enhanced versions of the flu shot. Plus, the shingles ...

In recent weeks, Health and Human Services Secretary Robert F. Kennedy Jr. has begun to dismantle decades of vaccine safety ...

Taking aim at a longtime target of anti-vaccine activists, CDC advisors said Thursday that the U.S. should not administer ...